Navigation Links
News from Molecular Medicine
Date:5/20/2010

Cystic Fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

Manhasset, NY (Vocus) May 20, 2010 -- In the latest issue of Molecular Medicine, cystic fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

In other studies in the latest issue of Molecular Medicine, a team of Brazilian scientists tested the activity of a novel angiotensin converting enzyme (ACE) in thrombus formation in animals that were either hypertensive or not. They reported that the pharmacological activation of the ACE2 receptor with the experimental ligand reduced platelet attachment to vessels and thrombus formation. These results suggest that this could be a potential lead compound for the treatment of thrombogenic diseases.

Other findings in the journal include a pivotal discovery of immune regulation of cancer cells, an endogenous factor that works in wound healing, a gene therapy study on Fabry Disease, a study on the immunological properties at work in Celiac disease, and a new molecular fingerprint of lung injury.

Molecular Medicine is published by The Feinstein Institute for Molecular Research. The peer-reviewed journal strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. The journal, a bimonthly publication, serves as a forum through which scientists and researchers can communicate recent discoveries to a multi-disciplinary, international audience interested in understanding and curing disease.

To listen to the latest podcast on these studies visit www.molmed.org/podcast.html.

###

Read the full story at http://www.prweb.com/releases/Molecular-Medicine/cystic-fibrosis/prweb4017864.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular marker could help spot pancreatic cancer early
2. Molecular discovery points to new therapies for brain tumors
3. USC researchers discover new molecular subtype of brain cancer
4. The Association for Molecular Pathology celebrates ruling in DNA patent case
5. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
6. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
7. Molecular pathways linked to sex, age affect outcomes in lung cancer
8. Ground Breaking Molecular Diagnostics Business Appoints New CEO
9. Select Topics in ALL: Molecular Characterization, Approaches to CNS Disease, and Post-remission Transplantation
10. Scientists show how molecular switch helps pancreatic cancer beat drugs
11. News from the Latest Issue of Molecular Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
News from Molecular Medicine
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology: